Scholarly monographs analyzing molecular targets, structural biophysics, and translational pharmacology in precision oncology.
Small GTPase biochemistry, switch II pocket dynamics, and the progression from covalent G12C inhibitors to pan-RAS therapeutics.
Targeted BRAF V600E inhibition in Erdheim-Chester Disease: basket trials, senescence, and rare disease drug development.
Transcriptional addiction, intrinsically disordered oncoproteins, and the structural biophysics of MYC-MAX inhibition.
Tryptophan catabolism, IDO1/TDO2 enzymatic signaling, and the immunometabolic checkpoint suppressing antitumor immunity.
Phenotypic plasticity of CD4⁺ T cells: cytolytic granule acquisition, immunosenescence, and exceptional human longevity.
Canonical Wnt/β-catenin signaling, macromolecular interface disruption, and resolving on-target off-tumor skeletal toxicity.
MCL-1 and mitochondrial outer membrane permeabilization: structural dynamics, rapid turnover, and cardiac safety bottlenecks.
Extracellular matrix remodeling, zymogen latency, and transitioning from pan-MMP inhibitors to protease-activated linkers.
Every claim in these essays is traceable to its primary source via the KiuClavis provenance graph.
Learn how it works →